载脂蛋白颗粒与心血管风险预测(来自前瞻性队列研究)。
Apolipoprotein Particle and Cardiovascular Risk Prediction (from a Prospective Cohort Study).
机构信息
Department of Epidemiology and Health Statistics, School of Public Health, Capital Medical University, Beijing, China; Municipal Key Laboratory of Clinical Epidemiology, Beijing, China; School of Public Health, Baotou Medical College, Baotou, China.
Department of Epidemiology and Health Statistics, School of Public Health, Capital Medical University, Beijing, China.
出版信息
Am J Cardiol. 2023 Aug 15;201:34-41. doi: 10.1016/j.amjcard.2023.05.052. Epub 2023 Jun 21.
The present study aimed to examine the association between discordant apolipoprotein B (Apo B) with low-density lipoprotein cholesterol (LDL-C) or non-high-density lipoprotein cholesterol (non-HDL-C) and cardiovascular disease (CVD) risk in the Chinese population and to determine whether adding information on Apo B to LDL-C and HDL-C improves CVD risk prediction. This study collected data from the China Health and Nutrition Survey from 2009 to 2015. Discordant Apo B with LDL-C and non-HDL-C were defined based on residual differences and medians. Logistic regression was used to examine the association between discordant Apo B with LDL-C or non-HDL-C and CVD risk. Areas under the receiver operating characteristic curve and categorical net reclassification improvement were utilized to assess the incremental predictive value of Apo B levels for CVD risk. A total of 7,117 participants were included, the mean age was 50.8 ± 14.3 years, 53.6% were female. During the 6-year follow-up, 207 CVD cases were identified. Participants with discordant high Apo B relative to LDL-C or non-HDL-C were at higher risk of CVD than those with the concordant group (odds ratio 1.38, 95% confidence interval 1.01 to 1.87; odds ratio 1.40, 95% confidence interval 1.01 to 1.94, respectively). However, Apo B had no significant contribution to the predictive value of the China atherosclerotic CVD (ASCVD) risk score (areas under the receiver operating characteristic curve 0.788 for China ASCVD score alone vs 0.790 for China ASCVD score plus Apo B). In conclusion, Apo B has the strongest association with CVD risk in healthy Chinese participants than LDL-C and non-HDL-C. However, it has minimal value in CVD risk assessment and discrimination.
本研究旨在探讨中国人群中载脂蛋白 B(Apo B)与低密度脂蛋白胆固醇(LDL-C)或非高密度脂蛋白胆固醇(non-HDL-C)不匹配与心血管疾病(CVD)风险之间的关系,并确定在 LDL-C 和 HDL-C 基础上增加 Apo B 信息是否能改善 CVD 风险预测。本研究数据来自 2009 年至 2015 年的中国健康与营养调查。基于残差和中位数,定义了 LDL-C 和 non-HDL-C 不匹配的 Apo B。采用 logistic 回归检验 LDL-C 或 non-HDL-C 不匹配的 Apo B 与 CVD 风险之间的关系。采用接受者操作特征曲线下面积和分类净重新分类改善评估 Apo B 水平对 CVD 风险的增量预测价值。共纳入 7117 名参与者,平均年龄为 50.8±14.3 岁,53.6%为女性。在 6 年随访期间,共发生 207 例 CVD 事件。与 LDL-C 或 non-HDL-C 不匹配的高 Apo B 参与者发生 CVD 的风险高于匹配组(比值比 1.38,95%置信区间 1.01 至 1.87;比值比 1.40,95%置信区间 1.01 至 1.94)。然而,Apo B 对中国动脉粥样硬化性心血管疾病(ASCVD)风险评分的预测价值无显著贡献(单独使用中国 ASCVD 评分的曲线下面积为 0.788,而联合使用中国 ASCVD 评分和 Apo B 的曲线下面积为 0.790)。总之,在健康的中国参与者中,Apo B 与 CVD 风险的关联强于 LDL-C 和 non-HDL-C。然而,其在 CVD 风险评估和区分方面的价值有限。